Table 1.
Baseline demographic, reproductive, prior post-menopausal hormone therapy use, breast cancer and tamoxifen treatment duration characteristics of study participants
| Baseline characteristics | Number of participants taking tamoxifen (N = 241)
|
|
|---|---|---|
| N/Mean/Median | Percent/SD/IQR | |
| Mean Age (years)a | 50.8 | ± 11.39 |
| Mean BMI (kg/m2)a | 24.19 | ± 3.91 |
| Self-reported ethnicity | ||
| Caucasian | 166 | 69 |
| Asian/East Asian | 54 | 22 |
| African American/Black | 3 | 1.5 |
| Latina/Hispanic | 13 | 5 |
| Pacific Islander | 1 | 0.5 |
| Other/Mixed | 1 | 0.5 |
| Declined/refused/do not know | 3 | 1.5 |
| Number married (yes) | 172 | 71 |
| Number full time working | 97 | 40 |
| Education levels | ||
| High school graduated or less | 9 | 4 |
| Some college | 45 | 19 |
| College graduated | 86 | 36 |
| Completed post-graduate degree | 95 | 39 |
| Socio economic status | ||
| Income < $50,000 | 34 | 14 |
| Income ≥ $50,000 to < $100,000 | 57 | 24 |
| Income ≥ $100,000 | 115 | 48 |
| Breast cancer (yes) | 238 | 99 |
| Had at least one other chronic health problem | 96 | 40 |
| Mean age at menarche (years)a | 12.70 | ± 1.31 |
| Pre-menopausal status at the time of diagnosis | 157 | 66 |
| Mean age at menopause at the time of diagnosis (years)ab | 47.94 | ± 6.20 |
| Had natural menopauseb | 50 | 63 |
| Had hysterectomy and oopherectomyb | 12 | 15 |
| Prior post-menopausal hormone therapy useb | 52 | 66 |
| Median length of post-menopausal hormone therapy use (years)bc | 4 | 2 – 9 |
| Median duration of tamoxifen treatment (months)b | 16 | 2 – 36 |
N number of participants; SD standard deviation; BMI body mass index; IQR interquartile range (Q1 = 25 percentile - Q3 = 75 percentile)
a
Data presented as Mean ± SD
b
Data reported for post-menopausal women at the time of diagnosis (N = 79, 34%)
c
Data presented as Median (IQR, Q1 and Q3)